Educational guide

SLU-PP-332 Dosage, Reconstitution & Mixing Trends | World Peptide Association

SLU-PP-332 Dosage, Reconstitution & Mixing Trends Discover SLU-PP-332 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions. SLU-PP-332 is a pan-agonist of the estrogen-related receptor (ERR) family — alp

Written by Peptide Therapy Guide Editorial TeamPublished August 29, 2026

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

SLU-PP-332 Dosage, Reconstitution & Mixing Trends

Discover SLU-PP-332 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.

SLU-PP-332 is a pan-agonist of the estrogen-related receptor (ERR) family — alpha, beta, and gamma — engineered as an "exercise mimetic" with preclinical rodent work showing improved running endurance, mitochondrial biogenesis, and fat loss without exercise. This data captures the dose amounts, vial sizes, and diluent volumes researchers most commonly select when working with SLU-PP-332.

47 SLU-PP-332 reconstitution calculations have been logged by the WPA community. The most common dose entered is 1mg (15 calculations). The median dose across all sessions is 800mcg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 5mg (41 sessions). The most common dosing frequency is daily (7x/week) (8 logged protocols), followed by 5x/week (1).

World Peptide Association aggregates anonymized peptide calculator data to show real-world dosing trends, reconstitution volumes, and vial size preferences across the research peptide community.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Key takeaways

SLU-PP-332 optimal dosing in rodent models is 10–30 mg/kg daily, translating to approximately 112–336 mg daily in humans using FDA allometric scaling.
The compound requires 4–8 weeks of sustained daily administration to reach peak mitochondrial biogenesis and endurance improvement—it is not an acute performance enhancer.
REV-ERB receptor expression follows circadian rhythms; dosing during high-receptor-expression windows (evening in humans) may maximize transcriptional effects.
Doses above 50 mg/kg in rodents (roughly 8 mg/kg human equivalent) show circadian disruption without additional performance benefit, defining the effective dosing ceiling.
SLU-PP-332 increases oxidative muscle fiber percentage and mitochondrial density through PGC-1α upregulation—the mechanism is fundamentally different from stimulant-based ergogenics.
No human clinical trials have been published as of early 2026, meaning safety, pharmacokinetics, and effective human dosing remain theoretical extrapolations from animal models.

realpeptides.co

comparison

SLU-PP-332 + GW501516 Comparison

While structurally different, both SLU-PP-332 and GW501516 target PPARδ receptors, making direct combination inadvisable due to receptor saturation concerns.[2] Comparative research suggest…

Source: mypeptidematch.com

comparison

Comparison of Dosing Protocol Design Strategies

When you're ready to design your own protocol, you're not just picking a number. You're choosing a strategy. Our team has seen labs use several valid approaches, each with its own trade-off…

Source: realpeptides.co

Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

SLU-PP-332 Dosage Chart

SLU-PP-332 is dosed at 1.25 mg–2.5 mg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only. Evidence Base: Preclinical only—in vivo mouse studies with intraperitoneal dosing (25–50 mg/kg twice daily). Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration. Murine dose range: 1250–2500 mcg daily (for a 25 g mouse), administered in two divided doses. Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe. Storage: Lyophilized: −20 °C (−4 °F); reconstituted: 2–8 °C (35.6–46.4 °F). PRECLINICAL RESEARCH COMPOUND: SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERRα/β/γ) studied exclusively in murine models for its ability to activate an aerobic-exercise gene program, enhance mitochondrial function, and improve endurance and cardiometabolic phenotypes[1][2][3]. No human trials have been conducted as of November 2025. This educational protocol reflects published murine regimens using intraperitoneal administration. Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read SLU-PP-332 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Source: peptidedosages.com ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

SLU-PP-332 Dosage, Reconstitution & Mixing Trends

SLU-PP-332 + GW501516 Comparison

Comparison of Dosing Protocol Design Strategies

SLU-PP-332 Dosage Chart

Peptide Therapy Guide Editorial Team

VIP Dosage, Reconstitution & Mixing Trends | World Peptide Association

Vilon Dosage, Reconstitution & Mixing Trends | World Peptide Association

Vesugen Dosage, Reconstitution & Mixing Trends | World Peptide Association

Vesilute Dosage, Reconstitution & Mixing Trends | World Peptide Association